RBC Capital initiated coverage of MoonLake Immunotherapeutics (MLTX) with an Outperform rating and $67 price target The firm’s analysis and feedback provides confidence lead drug sonelokimab will show clear, statistically significant benefits in the mid-year phase III hidradenitis suppurativa readout and 22%-24% placebo adjusted HiSCR75 delta, reflecting an incrementally better profile vs. currently marketed competitor bime, positioning sonelokimab as an early-line biologic of choice that helps drive a $2.5B per year sales opportunity, the analyst tells investors in a research note. The market opportunity in HS is likely to be underestimated, enabling long-term appreciation, the firm argues.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics: Advancing Sonelokimab with Promising Phase III VELA Program and Favorable Market Positioning
- MoonLake Immunotherapeutics Advances Clinical Trials in 2024
- MoonLake Immunotherapeutics: Promising Prospects for Sonelokimab in Inflammatory Diseases
- Optimistic Outlook for MoonLake Immunotherapeutics: Promising Developments and Market Opportunities for Sonelokimab
- Piper Sandler bullish on Avalo Therapeutics, initiates with an Overweight
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue